We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Genetic Test Enables Faster Diagnosis of Rare Diseases

By LabMedica International staff writers
Posted on 28 Nov 2025

Rare disease diagnosis often involves a long and uncertain search for the underlying genetic cause. More...

Traditional testing requires multiple separate analyses, although many patients remain without answers. A new clinical solution now offers a faster, more complete way to uncover hereditary conditions: a single test that maps the entire genome more accurately and captures complex variants that older methods miss.

The test, developed and implemented by Radboud University Medical Center (Nijmegen, Netherlands), in collaboration with Maastricht University Medical Center+ (Maastricht, Netherlands), is based on long-read genome sequencing, which measures DNA in much larger fragments and reconstructs all six billion building blocks with significantly higher completeness than short-read approaches. Radboudumc has now begun large-scale clinical use with 5,000 tests per year, initially targeting hereditary blindness and severe intellectual disabilities.

Study findings show that long-read sequencing increases diagnostic yield by more than ten percent for some rare diseases and can detect structural variations that are difficult to identify with conventional methods. The technique also captures DNA modifications that influence gene activity, offering deeper insight into disease mechanisms. Research suggests that ongoing analysis of these full-length genomes could raise the diagnostic uplift to as high as fifteen percent. Published evidence from genomic technology studies supports its suitability and reliability for routine clinical practice.

The introduction of this test is expected to replace around fifteen separate diagnostics, reduce time to diagnosis, and help uncover new hereditary causes of disease. For families, a definitive diagnosis brings clarity, emotional relief, and improved ability to connect with others facing similar conditions. Clinicians can also better assess future reproductive risk and provide more accurate prognostic information. As long-read sequencing becomes a new clinical standard, hospitals anticipate earlier answers and more comprehensive genetic insights for thousands of patients each year.

“Long read sequencing can replace fifteen other genetic tests in clinical practice, making diagnostics faster and more efficient,” said Professor of Genomic Technologies Alexander Hoischen. “I expect this will become the new standard for genome diagnostics and the only test we’ll perform in the future.”

Related Links:
Radboud University Medical Center
Maastricht University Medical Center+ 


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.